Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Onyx and UCSF Announce Oncology Innovation Alliance

Published: Tuesday, June 04, 2013
Last Updated: Tuesday, June 04, 2013
Bookmark and Share
The partnership will focus on drug discovery and development, and seeks to advance the broader scope of patient care.

Onyx Pharmaceuticals, Inc. and the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center announce the formation of the Oncology Innovation Alliance (OIA), a public-private partnership focusing on the discovery and development of novel therapies and their potential role in treating various types of hematologic cancers and solid tumors. 

“This collaboration will leverage expertise across UCSF and Onyx to further our collective understanding of cancer and hopefully translate scientific research rapidly from the laboratory to the clinic and, ultimately, to patients,” said Pablo J. Cagnoni, M.D., Executive Vice President, Global Research & Development and Technical Operations at Onyx Pharmaceuticals. “The UCSF Helen Diller Family Comprehensive Cancer Center is a recognized leader in oncology research and patient care, and Onyx is committed to forming strategic alliances that encourage innovation and the advancement of new treatments for patients.”

The alliance aims to transform cancer care by harnessing the expertise in fundamental science and medicine at both UCSF and Onyx to address the full continuum of that care, from prediction and diagnosis to new therapies and post-treatment monitoring, to identify opportunities to improve the patient experience and outcomes.

The partnership will focus on drug discovery and development, and seeks to advance the broader scope of patient care while contributing to the biological understanding of hematologic malignancies and solid tumors, discovering novel drug targets, identifying potential biomarkers to support patient selection and implementing innovative clinical development approaches.

“UCSF and Onyx share a vision of transforming care for patients with cancer, so we can precisely diagnose, treat and possibly even prevent cancer from occurring,” said Jeffrey Bluestone, PhD, Executive Vice Chancellor and Provost at UCSF. “Our goal is to create an umbrella partnership that enables us to work together to better understand the cascade of events within a cell that leads to disease, and find innovative ways to use that knowledge to diagnose and treat patients far more precisely than we can today.” 

A joint steering committee comprised of representatives from Onyx and UCSF will provide oversight of the alliance. The term of the agreement extends for three years. Financial terms of the collaboration were not disclosed.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Cell Cargo Ships in Near Future?
Virus-inspired container design may lead to cell cargo ships following construction of ten large, two-component, icosahedral protein complexes.
Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer
The NIH study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Understanding Treatment Resistant Melanoma
Researchers have determined how advanced melanoma becomes resistant; a development toward developing treatments.
Liquid Biopsies: DNA Size Matters
Study finds circulating tumour DNA can be distinguished from healthy DNA through fragment size identification.
Unravelling the Roots of Insect’s Waterproof Coating
Researchers have identified the genes that control cuticular lipid production in Drosophila, by performing an RNAi screen and using Direct Analysis in Real Time and GC-MS.
Identifying Cancer Drug Targets Using 3D-Modelling
Researchers are now able to model genetic mutations manipulation of proteins that can potentially drive cancer.
Improving Tumour Therapy with Nanoparticles
UHN nanoparticle called PEARLs is a promising utilisation of photo-thermal therapy for cancer treatment.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!